Drug developer Human Genome Sciences Inc. reported a larger fourth-quarter loss as expenses related to its lupus drug candidate Benlysta grew, and revenue decreased.
ATCC offers primary cardiomyocytes isolated from adult human tissue. Unlike cardiomyocytes derived from human ES or iPS cells, these heart muscle cells propagate in culture with high viability and plating efficiency.
The PHD ULTRA Syringe Pump drug and cell delivery system from Harvard Apparatus has been optimized to provide highly accurate and precise injections of low nanoliter to microliter volumes of cells and drugs that must be delivered to specific spatial locations.
Elan Drug Technologies announced that it won the Pipeline Value Creation Award at the Drug Delivery Partnerships meeting in Miami. The award recognises the value its platform technologies provide to client products.
Cancer drug developer Exelixis Inc. reported a smaller fourth-quarter loss following its restructuring. Exelixis said it posted a loss of $17.9 million, or 16 cents per share. A year earlier the company reported a loss of $28.8 million, or 27 cents per share.
A U.S.-Chile collaboration is bringing surgical patients closer to having a long-acting local anesthetic. In a randomized, double-blind trial, patients given neosaxitoxin, a new local anesthetic derived from algae, had significantly less postoperative pain.
A research team has identified and described two parts of the three-part system that pumps toxins from bacteria and allows them to resist antibiotics. A better understanding of the three parts could help medical researchers find ways to restore the effectiveness of antibiotics.
Tibotec Pharmaceuticals announced that two global, registrational phase 3 trials are recruiting patients to examine TMC435, its investigational hepatitis C protease inhibitor, in treatment-naïve adults with chronic genotype 1 hepatitis C virus.
Trophos SA, a pharmaceutical company developing innovative therapeutics for under-served needs in neurology and cardiology, announces the successful completion of its phase 1 dose escalation study of TRO40303, a novel mitochondria pore modulator.
A Stanford lawsuit that began as a patent infringement case against a drug company has evolved into a dispute over a federal law that promotes the commercialization of government-sponsored research and protects ownership rights of universities to inventions arising from government-sponsored research.
Costs associated with the recent amalgamation of the Biovail and Valeant drug businesses contributed to a $31.1-million net loss in the fourth quarter for Valeant Pharmaceuticals International, Inc.
Salix Pharmaceuticals Ltd. said it will likely have to provide more information to the Food and Drug Administration before gaining expanded approval for Xifaxan as a treatment for non-constipation irritable bowel syndrome.
Generic drug maker Mylan Inc. said that its fourth-quarter profit fell 38 percent on higher costs and charges, but adjusted results meet Wall Street expectations.
Upsher-Smith Laboratories is voluntarily expanding its previously announced recall of Jantoven Warfarin Sodium, USP, 3 mg Tablets to include additional products that were packaged on the same packaging line between May 17, 2010 and November 17, 2010.
Abbott Laboratories said a federal court of appeals has overturned a $1.67 billion judgment against the company related to patents on its best-selling drug Humira, which were challenged by rival Johnson & Johnson.